This article has been cited by
1Overexpression of SLC6A1 associates with drug resistance and poor prognosis in prostate cancer
Chaojiang Chen,Zhiduan Cai,Yangjia Zhuo,Ming Xi,Zhuoyuan Lin,Funeng Jiang,Zezhen Liu,Yueping Wan,Yu Zheng,Jianxin Li,Xing Zhou,Jianguo Zhu,Weide Zhong
BMC Cancer.2020;20(1)
[DOI]
2MicroRNA-223-3p regulates cell chemo-sensitivity by targeting FOXO3 in prostatic cancer
Qiang Feng,Peng He,Yu Wang
Gene.2018;658(1)152
[DOI]
3PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: Multicenter validation in patients from the Chinese Prostate Cancer Consortium
Xinqi Pei,Kaijie Wu,Yinghao Sun,Xu Gao,Xin Gou,Jun Xu,Fan Gao,Dalin He,Lei Li
Urologic Oncology: Seminars and Original Investigations.2020;38(1)2.e11
[DOI]
4Biomarkers of response to advanced prostate cancer therapy
Roberto Iacovelli,Chiara Ciccarese,Giovanni Schinzari,Ernesto Rossi,Brigida Anna Maiorano,Serena Astore,Tatiana D’Angelo,Antonella Cannella,Celeste Pirozzoli,Maria Anna Teberino,Francesco Pierconti,Maurizio Martini,Giampaolo Tortora
Expert Review of Molecular Diagnostics.2020;20(2)195
[DOI]
Feedback

Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal